Skip to main content

Table 5 Effect of APO E genotypes on plasma lipid and apolipoprotein profile in control and CAD groups.

From: Apolipoprotein gene polymorphisms and plasma levels in healthy Tunisians and patients with coronary artery disease

Genotype

E2/E3 (6 controls, 4 CAD)

E3/E3 (25 controls, 38 CAD)

E3/E4 (16 controls, 8 CAD)

P

*TC

    

   Controls

3.48 ± 0.35

4.04 ± 0.49

4.20 ± 0.35

0.005

   CAD

4.04 ± 1.07

4.58 ± 0.62

5.40 ± 0.67

0.007

*TG

    

   Controls

0.88 ± 0.10

0.73 ± 0.16

0.83 ± 0.19

0.767

   CAD

1.40 ± 0.77

1.74 ± 0.70

2.11 ± 0.93

0.314

*HDL-C

    

   Controls

0.95 ± 0.09

1.12 ± 0.09

1.07 ± 0.13

0.074

   CAD

0.86 ± 0.39

0.92 ± 0.25

0.93 ± 0.28

0.928

*LDL-C

    

   Controls

2.12 ± 0.38

2.56 ± 0.46

2.75 ± 0.38

0.014

   CAD

2.55 ± 0.29

2.82 ± 0.70

3.77 ± 0.60

0.017

*Apo A-I

    

   Controls

1.33 ± 0.29

1.36 ± 0.16

1.27 ± 0.13

0.797

   CAD

1.10 ± 0.12

1.03 ± 0.14

1.07 ± 0.13

0.939

*Apo B

    

   Controls

0.61 ± 0.06

0.73 ± 0.18

0.85 ± 0.16

0.016

   CAD

0.67 ± 0.16

0.98 ± 0.36

1.23 ± 0.29

0.038

*Apo E

    

   Controls

57.00 ± 6.07

53.77 ± 6.59

44.62 ± 5.40

0.001

   CAD

56.50 ± 20.74

42.65 ± 9.90

39.37 ± 8.76

0.043

  1. Data is expressed as mean ± SD; P: Probability values obtained by ANOVA for the comparison between E2/E3 and E3/E4 genotype groups.